Concepedia

Author

Martin Birkhofer

Bristol-Myers Squibb (United States)

Also Known As

M Birkhofer, M J Birkhofer, M. Birkhofer, Martin Birkhofer, Martin J. Birkhofer

26

Publications

1K

Citations

10

H-Index

12

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Columbia UniversityBristol-Myers Squibb (Germany)
MB

About

Martin Birkhofer is an author at Bristol-Myers Squibb (United States) specializing in cancer therapeutics, pharmacotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

31

2

Pharmacology

2

2

31

3

Cancer Therapeutics

2

2

31

4

Pathology

1

1

14

5

Clinical Trials

1

1

14

Martin Birkhofer

×

10

Publications

958

Citations

10

H-Index

YearCitations

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

Judith R. Abrams, Mark Lebwohl, Cynthia Guzzo,

Journal of Clinical Investigation

1999

598

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Manon Huizing, Laurence J. van Warmerdam, Hilde Rosing,

Journal of Clinical Oncology

1997

77

Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.

Kapil N. Bhalla, Martin Birkhofer, Z Arlin,

PubMed

1988

74

A Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

Diptee A. Gajjar, Frank LaCreta, Howard D. Uderman,

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

2000

61

The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells.

Kapil N. Bhalla, Martin Birkhofer, Steven Grant,

PubMed

1989

54

A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1

Timothy Kuzel, Steven T. Rosen, Aline Zimmer,

Cancer Biotherapy

1993

31

2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity

Kapil N. Bhalla, Martin Birkhofer, Steven Grant,

Blood

1989

19

Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

Neal J. Meropol, Daryl Sonnichsen, Martin Birkhofer,

Cancer Chemotherapy and Pharmacology

1999

17

A Phase II Trial of Zeniplatin in Metastatic Melanoma

Ian Olver, Michael Green, Wayne L. Peters,

American Journal of Clinical Oncology

1995

14

Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.

Kapil N. Bhalla, Martin Birkhofer, Z Arlin,

PubMed

1991

13

Page 1